At first, BRCA1 and BRCA2 mutations were identified as biomarkers in HRD, but there still exists some HRD cancer without BRCA1/2 mutations (88), indicating that some other HR-related genes would potentially affect PARPi sensitivity. The gene discussed is BRCA2; the disease is cancer.